Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); VISTA-16 Interim Color Looms as CV Becomes Investor Focus
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $13.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on positive chance success for blisibimod Phase 2 PEARL trial in lupus, and Phase 3 varespladib VISTA ACS data in 2012. Blisibimod is ANTH’s Phase 2 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial mid 2012. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS CV risk in H2/12 from the ongoing VISTA-16 trial."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.94 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on positive chance success for blisibimod Phase 2 PEARL trial in lupus, and Phase 3 varespladib VISTA ACS data in 2012. Blisibimod is ANTH’s Phase 2 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial mid 2012. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS CV risk in H2/12 from the ongoing VISTA-16 trial."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
